Company / Revenue
Pacira BioSciences, Inc. Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$726.4M
FY2025
5-year range
$421.0M / $726.4M
FY2021-FY2025
Trend
+3.6%
vs FY2024
Sector context
#51 of 155
Health Care
What the data says
At $726M, Pacira BioSciences, Inc.'s revenue ranks #51 of 155 in the Health Care sector. Revenue has increased for 8 consecutive years, from $249M in FY2017 to $726M in FY2025.
Based on SEC 10-K filings.
$726M in FY2025 with a 5-year CAGR of +16.6%.
Improved from $675M to $726M over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- +2.9%
- 5-Year CAGR
- +16.6%
- 10-Year CAGR
- -
Sector benchmark
#51 of 155 in Health CareTop 33% of 155This company $726.4M Sector average $4.5B
▼
-83.8% below sector average
Key checks
Key Insights
- Pacira BioSciences, Inc.'s revenue has grown for 8 consecutive years.
- 5-year CAGR of +16.6%, indicating consistent growth.
- In FY2025, revenue increased 3.6% year-over-year.
- Ranks #51 out of 155 companies in the Health Care sector.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Negative profit margin: -14.8%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $726.4M | +3.6% |
| FY2024 | $701.0M | +3.9% |
| FY2023 | $675.0M | +1.2% |
| FY2022 | $666.8M | +58.4% |
| FY2021 | $421.0M | +24.8% |
| FY2020 | $337.3M | +17.7% |
| FY2019 | $286.6M | +3.7% |
| FY2018 | $276.4M | +11.0% |
| FY2017 | $249.0M | -9.9% |
| FY2016 | $276.4M | +11.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026